Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
about
Regulation of immune cell function and differentiation by the NKG2D receptorCell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2DNatural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyExercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and ProgressionNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyImmune surveillance of unhealthy cells by natural killer cellsStructural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptorsNatural killer cells in human cancer: from biological functions to clinical applications"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer ImmunotherapyNKG2D Ligands in Tumor Immunity: Two Sides of a CoinNKG2D recruits two distinct adapters to trigger NK cell activation and costimulationIdentification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activationBACL is a novel brain-associated, non-NKC-encoded mammalian C-type lectin-like receptor of the CLEC2 familyContrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer CellsActivation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectorsAn six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit sheddingPerturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G.Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICAInnate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironmentThermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cellsThe activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure.Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.Dissecting the role of bone marrow stromal cells on bone metastases.DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1NKG2D-independent suppression of T cell proliferation by H60 and MICA.Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma.A basolateral sorting motif in the MICA cytoplasmic tail.Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related moleculesNKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational studyRe-educating natural killer cells.NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer.The requirement for NKG2D in NK cell-mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient.Oncogenic stress sensed by the immune system: role of natural killer cell receptorsGenetics, genomics, and evolutionary biology of NKG2D ligands.Recognition of tumors by the innate immune system and natural killer cells.
P2860
Q24635093-327A3259-B8DC-45E4-B690-C742CB591DD6Q24647598-08CCDA19-7AD2-458A-B452-C8F6BBD9C06CQ26771449-3AE4ED6F-FC4F-4105-91F6-B56E29C2D5DDQ26775189-CDF50469-090B-4379-AD6B-EA6DD83E7D37Q26797345-F035DFB8-208E-4B24-A3FB-385851ADC52BQ27003079-A437F662-DC63-4D20-AC7C-F4CEDABE4E8CQ27645060-39A19A8B-A322-4195-9462-2A22BED11F01Q27691427-765623C7-FEFC-480E-A9FF-B43ABCEE463EQ28081338-D29F9845-B0C6-40AD-B925-F50D251C4D22Q28083832-2109C68A-36F5-4712-95E9-154B84C7668BQ28214524-D5DD1C03-D798-46CB-A2EA-B5CED970BD5EQ28508164-ADE778ED-4CA5-4FE5-9A7C-D30BCC23E0ADQ28533797-092B98B0-661E-41B2-991D-506C001B16FDQ28550076-6F900748-0CB1-442D-80AC-22DC81648F32Q28744029-34B65B84-C620-4CD3-938B-7D45C98C2A90Q30489974-BF0DA1B2-0998-42D6-9AA1-27E1AC91E085Q30547087-766CA56F-E6D1-432C-BB76-19C9D8E7D2FFQ33410094-C8CF6ED3-2B98-4248-9729-DCD4D5C753E7Q33646189-A647605A-F4F8-41C1-A1C2-A0B1DB8DB1DBQ33825926-256BF800-5166-46F3-ABD7-785179CB1831Q33826833-13C064FB-C6B5-4FA9-97DD-A1E856378C3DQ33833898-C3A916CC-3BDF-415A-B854-CC0BC30264D4Q33836365-6ADC4EF5-E7ED-48E7-B73C-FA1117FDAB82Q33893091-989C6515-028A-4743-BE4D-6A8A8FB02CF1Q33904588-19B6956C-D91E-4359-9D9A-C498128CE45EQ33911460-57A49573-89EE-4069-A8DF-3122DCAAB428Q33914699-1B6AC59B-E123-4F5C-A21F-95291E738E58Q33920066-436B9CDE-1C1F-462E-B3CE-2F3816DFB97FQ33994392-A47EA747-EF21-4A25-BB0B-519E8399AC2FQ34015606-D1450D89-28CD-476D-A5B5-ED48F4797C6CQ34037679-2AD72138-5C20-4A47-89C0-757256B64F2DQ34068134-BEDD6BB1-5FE5-4FB7-9039-24E8DA5FD406Q34128134-EC06F7DA-2EA5-47F0-B227-2C363E9A8557Q34132372-0A54DDEF-D8ED-4DFA-87D2-6B4CC8FDF1FBQ34161487-7F52DA92-D21E-47D2-A3FE-BBFDA694CE99Q34197825-D397A095-80E3-4D88-8F5E-6A7F2043CF76Q34450450-41D6748D-B15D-405E-B549-98B23A3859CEQ34473267-843F9470-8635-4446-ACE2-6BD46C31327EQ34489980-78957DDB-8542-4CB3-8172-B4ADF2DC4E19Q34496462-08542315-3640-4F32-9A79-CFAA4ECB8D0A
P2860
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Ectopic expression of retinoic ...... class I-bearing tumor in vivo
@ast
Ectopic expression of retinoic ...... class I-bearing tumor in vivo
@en
type
label
Ectopic expression of retinoic ...... class I-bearing tumor in vivo
@ast
Ectopic expression of retinoic ...... class I-bearing tumor in vivo
@en
prefLabel
Ectopic expression of retinoic ...... class I-bearing tumor in vivo
@ast
Ectopic expression of retinoic ...... class I-bearing tumor in vivo
@en
P2093
P2860
P356
P1476
Ectopic expression of retinoic ...... class I-bearing tumor in vivo
@en
P2093
P2860
P304
11521-11526
P356
10.1073/PNAS.201238598
P407
P577
2001-09-18T00:00:00Z